TY - JOUR
T1 - Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway
AU - Cheng, Heng
AU - Chong, Youhoon
AU - Hwang, Inkyu
AU - Tavassoli, Ali
AU - Zhang, Yan
AU - Wilson, Ian A.
AU - Benkovic, Stephen J.
AU - Boger, Dale L.
N1 - Funding Information:
We gratefully acknowledge the financial support of the National Institute of Health (CA 63536, to D.L.B., I.A.W., and S.J.B.), and the Skaggs Institute for Chemical Biology. Y.Z. is a Skaggs Fellow.
PY - 2005/5/15
Y1 - 2005/5/15
N2 - The synthesis and evaluation of 10-methanesulfonyl-DDACTHF (1), 10-methanesulfonyl-5-DACTHF (2), and 10-methylthio-DDACTHF (3) as potential inhibitors of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) are reported. The compounds 10-methanesulfonyl-DDACTHF (1, Ki = 0.23 μM), 10-methanesulfonyl-5-DACTHF (2, Ki = 0.58 μM), and 10-methylthio-DDACTHF (3, Ki = 0.25 μM) were found to be selective and potent inhibitors of recombinant human GAR Tfase. Of these, 3 exhibited exceptionally potent, purine sensitive growth inhibition activity (3, IC 50 = 100 nM) against the CCRF-CEM cell line being 3-fold more potent than Lometrexol and 30-fold more potent than the parent, unsubstituted DDACTHF, whereas 1 and 2 exhibited more modest growth inhibition activity (1, IC 50 = 1.0 μM and 2, IC50 = 2.0 μM).
AB - The synthesis and evaluation of 10-methanesulfonyl-DDACTHF (1), 10-methanesulfonyl-5-DACTHF (2), and 10-methylthio-DDACTHF (3) as potential inhibitors of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) are reported. The compounds 10-methanesulfonyl-DDACTHF (1, Ki = 0.23 μM), 10-methanesulfonyl-5-DACTHF (2, Ki = 0.58 μM), and 10-methylthio-DDACTHF (3, Ki = 0.25 μM) were found to be selective and potent inhibitors of recombinant human GAR Tfase. Of these, 3 exhibited exceptionally potent, purine sensitive growth inhibition activity (3, IC 50 = 100 nM) against the CCRF-CEM cell line being 3-fold more potent than Lometrexol and 30-fold more potent than the parent, unsubstituted DDACTHF, whereas 1 and 2 exhibited more modest growth inhibition activity (1, IC 50 = 1.0 μM and 2, IC50 = 2.0 μM).
UR - http://www.scopus.com/inward/record.url?scp=17444399660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17444399660&partnerID=8YFLogxK
U2 - 10.1016/j.bmc.2004.12.004
DO - 10.1016/j.bmc.2004.12.004
M3 - Article
C2 - 15848770
AN - SCOPUS:17444399660
SN - 0968-0896
VL - 13
SP - 3577
EP - 3585
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 10
ER -